Raymond James analyst Gary Nachman notes AbbVie (ABBV) announced the proposed acquisition of Bretisilocin from Gilgamesh Pharmaceuticals for a deal value of up to $1.2B, which the firm believes is a very solid addition to the company’s Neuro pipeline. Bretisilocin is Gilgamesh’s lead asset currently in Phase 2 for Major Depressive Disorder with a novel MOA, and recently announced positive Phase 2a data showed a compelling profile in both efficacy and safety. Bretisilocin fits in “very nicely” with AbbVie’s Neuro franchise where there will be lots of synergies in a very large MDD category, Raymond James adds. The firm believes this deal should not have come as a surprise since it was previously speculated in a news report about a month ago, and AbbVie already had a collaboration in place with Gilgamesh for preclinical assets in various psychiatric disorders. Raymond James reiterates an Outperform rating on AbbVie’s rating.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie to acquire Gilgamesh’s bretisilocin program for up to $1.2B
- AbbVie’s IMGN151 Study: A New Hope for Recurrent Gynecological Cancers
- AbbVie’s Promising CLL Study: A Potential Game-Changer for Investors
- AbbVie’s Promising Phase 3 Study on Upadacitinib for Hidradenitis Suppurativa
- AbbVie’s New Study to Shed Light on Disease Burden in Dermatology